R-Pharm US buys breast cancer drug from Bristol-Myers for an undisclosed amount
R-Pharm US said it has acquired the breast cancer drug Ixempra (ixabepilone) from Bristol-Myers Squibb (NYSE: BMY) for an undisclosed sum to set off its foray into the US market.
The company in a statement said under the terms of the deal it will be responsible for manufacture, distribution, sales and reimbursement of the drug. The company will be launching its sales operations in October. The acquisition is in line with the company’s strategy to buy and market products in the cancer and immunology segment.
Demetrios Kydonieus, chief business officer of R-Pharm US, said: "Our strategy is to identify and acquire underserved pharmaceutical products that can become growth brands with focused and effective commercialization support in the US market."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze